RADIATION THERAPY ONCOLOGY GROUP
RTOG 0126
|
A PHASE III RANDOMIZED STUDY OF HIGH DOSE 3D-CRT
VERSUS STANDARD DOSE 3D-CRT IN PATIENTS TREATED FOR LOCALIZED
PROSTATE CANCER
(Closed to patient accrual as of 8/20/08.)
|
RTOG 0232
|
A PHASE III STUDY COMPARING COMBINED EXTERNAL BEAM
RADIATION AND TRANSPERINEAL INTERSTITIAL PERMANENT BRACHYTHERAPY
WITH BRACHYTHERAPY ALONE FOR SELECTED PATIENTS WITH INTERMEDIATE
RISK PROSTATIC CARCINOMA |
NSABP B-39/
RTOG 0413
|
A RANDOMIZED PHASE III STUDY
OF CONVENTIONAL WHOLE BREAST IRRADIATION (WBI)
VERSUS PARTIAL BREAST IRRADIATION (PBI)
FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER |
|
A PHASE III RANDOMIZED STUDY OF HYPOFRACTIONATED
3D-CRT/IMRT VERSUS CONVENTIONALLY FRACTIONATED
3D-CRT/IMRT IN PATIENTS WITH FAVORABLE-RISK PROSTATE CANCER
|
|
A PHASE II STUDY OF INTENSITY MODULATED RADIATION
THERAPY (IMRT) TO THE PELVIS +/- CHEMOTHERAPY FOR
POST-OPERATIVE PATIENTS WITH EITHER ENDOMETRIAL OR
CERVICAL CARCINOMA
|
|
A PHASE III TRIAL EVALUATING THE ADDITION OF CETUXIMAB TO
PACLITAXEL, CISPLATIN, AND RADIATION FOR PATIENTS WITH
ESOPHAGEAL CANCER WHO ARE TREATED WITHOUT SURGERY
|
|
A PHASE I TRIAL OF HIGHLY CONFORMAL
RADIATION THERAPY FOR PATIENTS WITH LIVER METASTASES
|
|
A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND
3DCRT/IMRT VS. AS AND 3DCRT/IMRT FOLLOWED BY
CHEMOTHERAPY WITH DOCETAXEL AND PREDNISONE
FOR LOCALIZED, HIGH-RISK PROSTATE CANCER
|
|
A RANDOMIZED PHASE III TRIAL OF CONCURRENT ACCELERATED
RADIATION AND CISPLATIN VERSUS CONCURRENT ACCELERATED
RADIATION, CISPLATIN, AND CETUXIMAB (C225)
[FOLLOWED BY SURGERY FOR SELECTED PATIENTS]
FOR STAGE III AND IV HEAD AND NECK CARCINOMAS
|
|
A PROSPECTIVE PHASE II TRIAL OF TRANSPERINEAL
ULTRASOUND-GUIDED BRACHYTHERAPY FOR LOCALLY RECURRENT
PROSTATE ADENOCARCINOMA FOLLOWING EXTERNAL BEAM
RADIOTHERAPY
|
|
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH
PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPORT)
IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL
PROSTATECTOMY
|
|
PHASE II TRIAL OF OBSERVATION FOR LOW-RISK MENINGIOMAS AND OF RADIOTHERAPY FOR INTERMEDIATE- AND HIGH-RISK MENINGIOMAS
|
|
A PHASE II STUDY OF CONCURRENT CHEMORADIOTHERAPY USING THREE-DIMENSIONAl
CONFORMAL RADIOTHERAPY (3D CRT) OR INTENSITY-MODULATED RADIATION ThERAPY
(IMRT) + BEVACIZUMAB (BV) FOR LOCALLY OR REGIONALLY ADVANCED NASOPHARYNGEAL CANCER
|
|
A RANDOMIZED PHASE III COMPARISON OF STANDARD-DOSE (60 Gy)
VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT
AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB
(IND #103444) IN PATIENTS WITH STAGE IIIA/IIIB
NON-SMALL CELL LUNG CANCER |
|
A PHASE II TRIAL OF STEREOTACTIC BODY RADIATION THERAPY (SBRT)
IN THE TREATMENT OF PATIENTS WITH OPERABLE STAGE I/II
NON-SMALL CELL LUNG CANCER
|
|
A RANDOMIZED PHASE II TRIAL OF CHEMORADIOTHERAPY
VERSUS CHEMORADIOTHERAPY AND VANDETANIB FOR HIGH-RISK
POSTOPERATIVE ADVANCED SQUAMOUS CELL CARCINOMA
OF THE HEAD AND NECK
|
|
ADJUVANT 3DCRT/IMRT IN COMBINATION WITH ANDROGEN SUPPRESSION
AND DOCETAXEL FOR HIGH RISK PROSTATE CANCER PATIENTS
POST-PROSTATECTOMY: A PHASE II TRIAL
|
|
A PHASE I/II TRIAL OF SAMARIUM-153 FOLLOWED BY SALVAGE PROSTATIC FOSSA
IRRADIATION IN HIGH-RISK, CLINICALLY NON-METASTATIC PROSTATE CANCER
AFTER RADICAL PROSTATECTOMY
|
|
A PHASE II TRIAL OF COMBINED MODALITY THERAPY WITH GROWTH FACTOR
SUPPORT FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER
|
|
A PHASE II TRIAL OF IMAGE GUIDED PREOPERATIVE RADIOTHERAPY
FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY
|
|
PHASE II/III STUDY OF IMAGE-GUIDED RADIOSURGERY/SBRT
FOR LOCALIZED SPINE METASTASIS
|
|
A PHASE II RANDOMIZED STUDY FOR PATIENTS WITH MUSCLE-INVASIVE
BLADDER CANCER EVALUATING TRANSURETHRAL SURGERY AND CONCOMITANT
CHEMORADIATION BY EITHER BID IRRADIATION PLUS 5-FLOUROURACIL
AND CISPLATIN OR QD IRRADIATION PLUS GEMCITABINE FOLLOWED BY
SELECTIVE BLADDER PRESERVATION AND GEMCITABINE/CISPLATIN
ADJUVANT CHEMOTHERAPY
|
|
PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY
|
|
SEAMLESS PHASE I/II STUDY OF STEREOTACTIC LUNG RADIOTHERAPY (SBRT)
FOR EARLY STAGE, CENTRALLY LOCATED,
NON-SMALL CELL LUNG CANCER (NSCLC) IN MEDICALLY INOPERABLE PATIENTS
|
|
A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
|
|
A PHASE II EVALUATION OF PREOPERATIVE CHEMORADIOTHERAPY
UTILIZING INTENSITY MODULATED RADIATION THERAPY (IMRT)
IN COMBINATION WITH CAPECITABINE AND OXALIPLATIN FOR
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
|
|
PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
|
|
RANDOMIZED, PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS CEDIRANIB VERSUS CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS PLACEBO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
|
|
RANDOMIZED PHASE II STUDY OF PRE-OPERATIVE CHEMORADIOTHERAPY +/- PANITUMUMAB (IND #110152) FOLLOWED BY CONSOLIDATION CHEMOTHERAPY IN POTENTIALLY OPERABLE LOCALLY ADVANCED (STAGE IIIA, N2+) NON-SMALL CELL LUNG CANCER
|
|
A PHASE III TRIAL EVALUATING BOTH ERLOTINIB AND CHEMORADIATION AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA
|
-
|
A RANDOMIZED PHASE II STUDY OF CONCURRENT INTENSITY MODULATED RADIATION THERAPY (IMRT), PACLITAXEL AND PAZOPANIB (NSC 737754)/PLACEBO, FOR THE TREATMENT OF ANAPLASTIC THYROID CANCER
|
|
PHASE I/II TRIAL OF CONCURRENT RAD001 (EVEROLIMUS) WITH TEMOZOLOMIDE/RADIATION FOLLOWED BY ADJUVANT RAD001/TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
|
|
A RANDOMIZED PHASE II STUDY COMPARING 2 STEREOTACTIC BODY RADIATION THERAPY (SBRT) SCHEDULES FOR MEDICALLY INOPERABLE PATIENTS WITH STAGE I PERIPHERAL NON-SMALL CELL LUNG CANCER
|
|
A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB
FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER
|
|
A PHASE II STUDY OF POSTOPERATIVE INTENSITY MODULATED RADIATION THERAPY (IMRT)
WITH CONCURRENT CISPLATIN AND BEVACIZUMAB FOLLOWED BY CARBOPLATIN AND
PACLITAXEL FOR PATIENTS WITH ENDOMETRIAL CANCER
|
|
ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL
|
|
A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1 BLADDER CANCER TO EVALUATE SELECTIVE BLADDER PRESERVING TREATMENT BY RADIATION THERAPY CONCURRENT WITH CISPLATIN CHEMOTHERAPY FOLLOWING A THOROUGH TRANSURETHRAL SURGICAL RE-STAGING
|
|
A PHASE II TRIAL OF HIPPOCAMPAL AVOIDANCE DURING WHOLE BRAIN RADIOTHERAPY FOR BRAIN METASTASES
|
|
RANDOMIZED PHASE II STUDY COMPARING PROPHYLACTIC CRANIAL IRRADIATION ALONE TO PROPHYLACTIC CRANIAL IRRADIATION AND CONSOLIDATIVE EXTRA-CRANIAL IRRADIATION FOR EXTENSIVE DISEASE SMALL CELL LUNG CANCER (ED-SCLC)
|
|
A RANDOMIZED PHASE II TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOR FAVORABLE RISK PROSTATE CANCER
|
|
A PHASE III TRIAL OF ACCELERATED WHOLE BREAST IRRADIATION
WITH HYPOFRACTIONATION PLUS CONCURRENT BOOST
VERSUS STANDARD WHOLE BREAST IRRADIATION
PLUS SEQUENTIAL BOOST FOR EARLY-STAGE BREAST CANCER
|
|
PHASE II - ADJUVANT CONCURRENT RADIATION AND CHEMOTHERAPY VS RADIATION ALONE IN RESECTED HIGH-RISK MALIGNANT SALIVARY GLAND TUMORS
|
|
A PHASE III TRIAL EVALUATING THE ADDITION OF TRASTUZUMAB TO TRIMODALITY
TREATMENT OF HER2-OVEREXPRESSING ESOPHAGEAL ADENOCARCINOMA
|
|
PHASE II RANDOMIZED TRIAL OF PROPHYLACTIC MANUKA HONEY FOR THE
REDUCTION OF CHEMORADIATION THERAPY INDUCED ESOPHAGITIS-RELATED
PAIN DURING THE TREATMENT OF LUNG CANCER
|
|
PHASE II STUDY OF REPEAT BREAST PRESERVING SURGERY AND
3D-CONFORMAL PARTIAL BREAST RE-IRRADIATION (PBRI) FOR
LOCAL RECURRENCE OF BREAST CARCINOMA
|
|
PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY
IN HPV-ASSOCIATED OROPHARYNX CANCER
|
|
RANDOMIZED PHASE III STUDY OF SUBLOBAR RESECTION (+/- BRACHYTHERAPY) VERSUS STEREOTACTIC BODY RADIAT
ION THERAPY IN HIGH RISK PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER (NSCLC) |
|
A PHASE I STUDY OF INDUCTION GANITUMAB (IND #113278) AND GEMCITABINE,
FOLLOWED BY GANITUMAB, CAPECITABINE, AND 3D-CONFORMAL RADIATION THERAPY
(3D-CRT) WITH SUBSEQUENT MAINTENANCE THERAPY
FOR LOCALLY ADVANCED PANCREATIC CANCER
|
|
RANDOMIZED PHASE II TRIAL OF INDIVIDUALIZED ADAPTIVE RADIOTHERAPY
USING DURING-TREATMENT FDG-PET/CT AND MODERN TECHNOLOGY
IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
|
|
RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY
FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA
|
|
PHASE III TRIAL OF DOSE ESCALATED RADIATION THERAPY AND STANDARD ANDROGEN DEPRIVATION THERAPY (ADT) WITH A GNRH AGONIST VS. DOSE ESCALATED RADIATION THERAPY AND ENHANCED ADT WITH A GNRH AGONIST AND TAK-700 FOR MEN WITH HIGH RISK PROSTATE CANCER
|
|
A RANDOMIZED PHASE III STUDY OF STANDARD VS. IMRT PELVIC RADIATION FOR POST-OPERATIVE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (TIME-C)--RTOG CCOP STUDY
|
|
RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA
|
|
RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK
|
NSABP B-51/
RTOG 1304
|
A RANDOMIZED PHASE III CLINICAL TRIAL EVALUATING POST-MASTECTOMY CHESTWALL AND REGIONAL NODAL XRT AND POST-LUMPECTOMY REGIONAL NODAL XRT IN PATIENTS WITH POSITIVE AXILLARY NODES BEFORE NEOADJUVANT CHEMOTHERAPY WHO CONVERT TO PATHOLOGICALLY NEGATIVE AXILLARY NODES AFTER NEOADJUVANT CHEMOTHERAPY
|
|
|
